Halozyme Therapeutics, Inc. (FRA:RV7)

Market Cap	7.10B +5.3%
Revenue (ttm)	1.06B +31.2%
Net Income	507.54M +51.7%
EPS	4.04 +56.7%
Shares Out	n/a
PE Ratio	13.99
Forward PE	8.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26
Average Volume	55
Open	58.56
Previous Close	59.00
Day's Range	58.56 - 59.66
52-Week Range	42.45 - 66.90
Beta	n/a
RSI	54.63
Earnings Date	Feb 18, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 350
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RV7

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD